Background Th e prevalence of resistance to clarithromycin and metronidazole has considerably increased, with a corresponding decrease in the eradication rate for Helicobacter pylori (H. pylori) infection. Primary resistance to amoxicillin is extremely low, and esomeprazole was found to exert a noteworthy antimicrobial activity in vitro against H. pylori. A dual therapy with high-dose of esomeprazole coupled with high-dose amoxicillin might be therefore an ideal fi rst-line treatment for H. pylori eradication. We aimed to assess the effi cacy of a fi rst-line 10-day, high-dose dual therapy consisting of amoxicillin and esomeprazole to eradicate H. pylori infection.
Introduction
Helicobacter pylori (H. pylori) infection causes peptic ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer [1, 2] . Standard treatments for H. pylori infection endorsed by the U.S. as well as European scientifi c societies and by regulatory authorities rely on clarithromycin, metronidazole, or amoxicillin in conjunction with gastric acid inhibitors [3] [4] [5] [6] . Disappointingly, the prevalence of clarithromycin and metronidazole resistance has increased substantially in recent years, and a corresponding decrease has occurred in the eradication rate for H. pylori infection [7, 8] . Indeed, fi rst-line therapy success rate has declined to unacceptable levels in most Western countries [9] . In addition, the primary resistance to levofl oxacin -an antibiotic generally used for second-line therapy -is also increasing in several countries [7, 8] . Consequently, to treat H. pylori eradication failure patients is progressively more diffi cult, suggesting that a highly successful fi rst-line regimen is the key to contrast the phenomenon.
Considering that the availability of new antibiotics against H. pylori is uncertain in the next few years [10] , the identifi cation of new regimens, including the currently available molecules, able to achieve a >90% eradication rate is urgently needed. Such a regimen would need to overcome the increasing prevalence [12, 13] , the primary resistance to amoxicillin is extremely low in several countries, with a prevalence rate as low as <1% (95% CI: 0.06-1.06) and 3% in Europe and the U.S., respectively [7, 8] . However, amoxicillin is largely inactivated by low pH values present in the stomach [14, 15] , so that a simultaneous proton pump inhibitor (PPI) therapy is mandatory [16] . In addition, a deep suppression of gastric acid secretion, allowing to achieve pH value >6, is expected to favor antibacterial activity of amoxicillin in the gastric juice [14] . However, such a condition is rarely achieved in Caucasian subjects with standard dose of PPIs, due to the genetic polymorphism of hepatic P450 cytochrome responsible of PPI metabolism. Indeed, as many as >95% of Caucasians are rapid or intermediate metabolizers of PPIs [17] , suggesting that an increased dose is needed in the majority of Caucasian subjects. On the other hand, among PPIs, esomeprazole was found to exert a greater antimicrobial activity in vitro against H. pylori compared to omeprazole, which could help improve the success rate of eradication regimens [18] . Based on these considerations, a dual therapy with high-dose esomeprazole, which increases intragastric pH and exerts a direct anti-bacterial activity, coupled with high-dose amoxicillin, against which primary resistance is extremely low, would be an ideal fi rst-line treatment for H. pylori eradication.
We therefore designed this proof of concept study to assess the effi cacy of such a high-dose dual therapy as fi rst-line treatment in H. pylori-infected patients.
Patients and methods

Patients
Th is was an open-label, study performed in 4 Italian Hospitals (1 Northern; 2 Central, and 1 Southern Italy). In each participating center, consecutive adult (>18 years) patients, who underwent upper endoscopy due to dyspeptic symptoms and found to be infected with H. pylori at routine histological assessment, were invited to participate. Exclusion criteria were: 1) previous H. pylori eradication therapy; 2) known or suspected allergy to penicillin; 3) use of PPI or antibiotics in the previous 4 weeks; 4) previous surgery of upper gastrointestinal tract; 5) severe diseases (cardiovascular, pulmonary, renal or hepatic); 6) malignant disease during the previous 5 years; 7) alcohol abuse or severe psychiatric or neurologic disorders; 8) pregnancy or lactation; and 9) refusal to consent.
Therapy regimen
All patients received a 10-day, high-dose dual therapy comprising esomeprazole (40 mg t.i.d) and amoxicillin (1 g t.i.d.). The PPI was given half an hour before breakfast, lunch and dinner, whilst amoxicillin just after these meals. At the end of the treatment, compliance to therapy and reported side-effects were assessed by a personal interview. At least 4 weeks after the end of the treatment a 13 C urea breath test (UBT) was performed to evaluate H. pylori eradication rate.
Statistical analysis
Th e eradication rate with 95% confi dence intervals was calculated. Before pooling the estimates, a Fisher's exact test was performed to exclude a signifi cant heterogeneity among the diff erent centers. Based on the study design (pilot study), data of only those patients who took ≥80% of prescribed drugs, and underwent UBT control were considered.
Results
A total of 56 (male/female = 32/24; mean age: 51.3±13.7 years) patients agreed to participate in the study. All patients confirmed having taken all the prescribed drugs, but two patients who performed the therapy for 9 and 8 days, respectively. All these patients underwent the scheduled UBT control. As shown in Table 1 , H. pylori infection was successfully cured in 87.5% (95% CI=78.8•96.2), without a statistically significant difference among the participating centers. Overall, 5 (8.9%; 1.5•16.4%) patients complained of side-effects (2 vomiting, 2 nausea, and 1 mild diarrhea), but only the 2 patients with vomiting early interrupted the treatment (at 9 and 8 days). All side-effects were selflimited.
Discussion
Th e success rate of standard triple therapies for H. pylori eradication is decreasing worldwide [19] , suggesting the need of novel therapy regimens. Since newer agents with elevated activity against such an infection, including resistant strains, are still lacking [10] , optimizing the use of available antibiotics would be advantageous. With this purpose, we tested the effi cacy of a fi rst-line, high-dose esomeprazoleamoxicillin dual therapy. Th e rationale of such a regimen consisted in coupling a deep suppression of acid secretion achieved with high-dose esomeprazole which would favor the effi cacy of high-dose amoxicillin for which primary resistance in H. pylori isolates is very uncommon. Our study showed an interestingly high effi cacy of this regimen, approaching a 90% success rate in our series. Of note, such a high cure rate was achieved using a regimen lasting only 10 days, suggesting that a longer 14-day therapy could perform better, particularly when considering the high tolerability we observed. Indeed, a 14-day high-dose dual therapy regimen with omeprazole 120 mg and amoxicillin 2.25 g achieved an 89% eradication rate in duodenal ulcer patients [20] , and 96% in 126 MALTlymphoma patients [21] . Likewise, a 95.5% eradication rate was achieved with a high-dose lansoprazole and amoxicillin 2 g fi rst-line therapy in Japan [22] . In addition, a recent study performed in Taiwan showed that a high-dose dual therapy with rabeprazole 20 mg and amoxicillin 750 mg, all given q.i.d. for 14 days, achieved a 95.3% cure rate in naïve patients [23] . Interestingly, high-dose dual therapy with omeprazole 20 mg q.i.d and amoxicillin 1 g b.i.d achieved a signifi cantly higher eradication rate than 14-day triple therapy in Turkey [24] , where achieving H. pylori eradication is notoriously diffi cult [25] . On the contrary, a disappointing 53.8% success rate was achieved in 13 patients using dexlansoprazole 120 mg and amoxicillin 1 g, both b.i.d. for 14 days [26] . Moreover, the attempt to improve a high-dose dual therapy with esomeprazole 40 mg b.i.d. and amoxicillin 1 g t.i.d for 10 days by adding metronidazole did not appear to be advantageous, the eradication rates being 82.4% and 88.2% at intention-to-treat and per protocol analysis, respectively [27] . Overall, all these observations would suggest that a study testing our proposed high-dose dual regimen with esomeprazole 40 mg and amoxicillin 1 g, both t.i.d., for 14 days is urged. Th e usefulness of a study is further supported by the high tolerability of such a regimen, for which the incidence of adverse events was reported to be not signifi cantly superior to those observed in the comparison arms [20, 22, 28] .
In conclusion, this is the first Italian study showing that a 10-day, high-dose dual therapy with esomeprazole and amoxicillin could achieve high eradication rates, suggesting that the efficacy of a longer 14-day regimen should be tested.
Summary Box
What is already known:
• Th e success rate of standard triple therapies for Helicobacter pylori (H. pylori) infection has declined to unacceptable levels • Th e prevalence of primary resistance towards clarithromycin and metronidazole is high, whilst that towards amoxicillin remains extremely low
What the new fi ndings are:
• A novel 10-day dual therapy with high-dose of esomeprazole coupled with high-dose amoxicillin was found to be acceptably eff ective and highly tolerated as a fi rst-line therapy
